SIST EN ISO 18562-2:2024 PDF
Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 2: Tests for emissions of particulate matter (ISO 18562-2:2024)
Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 2: Tests for emissions of particulate matter (ISO 18562-2:2024)
- Статус документа:
- Действующий
- Формат:
- Электронный (PDF)
- Количество страниц:
- 27
- Дата публикации:
- 13 ноября 2024 г.
- Издание:
- ISO 18562-2:2024
- ICS:
- 11.040.10
This document specifies tests for the emissions of particulate matter from the gas pathways of a medical device, its parts or accessories, which are intended to provide respiratory care or supply substances via the respiratory tract to a patient in all environments. The tests of this document are intended to quantify particles from 0,25 µm diameter to 10 µm diameter that are emitted by the medical device, its parts or accessories into the respirable gas stream. This document establishes acceptance criteria for these tests. This document does not address nanoparticles. Insufficient data exist to establish exposure limits for particles less than 0,25 µm diameter. This document does not address particles larger than 10 µm diameter. These particles are deposited in the nasal cavity. Additional information can be needed for medical devices or accessories that bypass the nose. This is outside the scope of this document but can be required by some authorities having jurisdiction. This document therefore adopts the same approach as the US Environmental Protection Agency (EPA) in setting limits based solely on particle size and not their chemistry. This document addresses potential contamination of the gas stream arising from the gas pathways, which is then conducted to the patient. This document applies over the expected lifetime of the medical device in normal use and takes into account the effects of any intended processing. This document does not address biological evaluation of the particles that are deliberately released by a nebulizer (i.e. the therapeutic agent). This document does not address biological evaluation of the surfaces of gas pathways that have direct contact with the patient. The requirements for direct contact surfaces are found in the ISO 10993 series. Medical devices, parts or accessories, containing gas pathways that are addressed by this document, include, but are not limited to, ventilators, anaesthesia workstations (including gas mixers), breathing systems, oxygen conserving devices, oxygen concentrators, nebulizers, low-pressure hose assemblies, humidifiers, heat and moisture exchangers, respiratory gas monitors, respiration monitors, masks, medical respiratory personal protective equipment, mouth pieces, resuscitators, breathing tubes, breathing systems filters, Y-pieces, and any breathing accessories intended to be used with such devices. The enclosed chamber of an incubator, including the mattress, and the inner surface of an oxygen hood are considered to be gas pathways and are also addressed by this document. This document does not address contamination already present in the gas supplied from the gas sources while medical devices are in normal use. EXAMPLE Contamination arriving at the medical device from gas sources such as medical gas pipeline systems (including the non-return valves in the pipeline outlets), outlets of pressure regulators connected or integral to a medical gas cylinder or room air taken into the medical device is not addressed by ISO 18562 (all parts).
Abstract
Overview
EN ISO 18562-2:2024 (ISO 18562-2:2024) specifies test methods and acceptance criteria for particulate matter emissions from breathing gas pathways of medical devices. It applies to devices, parts and accessories that deliver or monitor respiratory gases to patients - for example ventilators, anaesthesia workstations, oxygen concentrators, humidifiers, masks, incubator chambers and breathing circuits. The standard quantifies particles in the 0.25 µm to 10 µm diameter range that can enter the respirable gas stream and establishes test setups and reporting requirements. It intentionally excludes nanoparticles (<0.25 µm), particles >10 µm, contamination already present in supplied gas sources, and therapeutic aerosols deliberately generated by nebulizers.
Key topics and requirements
- Scope and applicability: Tests apply over the expected lifetime in normal use and account for intended processing (e.g., sterilization, cleaning).
- Particle size focus: Emissions are measured for particles between 0.25 µm and 10 µm; nanoparticles and >10 µm particles are out of scope.
- Testing approaches: Describes single-filter and double-filter test setups, methods for measuring particle concentrations, and procedures for devices with time-varying emissions.
- Measurement techniques: Guidance on using particle counters and reporting particulate matter by size fractions to quantify respirable contamination.
- Acceptance criteria: The document establishes acceptance criteria for particulate emissions (see the standard for numeric limits and test conditions).
- Reporting and documentation: Specifies required test reports and data elements to support biocompatibility risk assessment and regulatory submissions.
- Harmonization: Adopts an EPA-like approach by setting limits based on particle size rather than particle chemistry.
Applications and who uses this standard
- Medical device manufacturers - design verification and risk assessment for breathing gas pathways.
- Test laboratories and QA teams - perform standardized particulate emission testing and produce compliance reports.
- Regulatory and compliance professionals - demonstrate conformity with biocompatibility expectations and support Medical Device Regulation (MDR/MDD) submissions where applicable.
- R&D and product development - guide material selection, manufacturing and processing to reduce respirable particulate contamination.
- Clinical engineers and hospital procurement - evaluate device safety regarding respirable particle emissions.
Related standards
- EN/ISO 18562-1:2024 - overall biocompatibility evaluation and testing within a risk management process.
- ISO 10993 series - biological evaluation of materials in direct patient contact (not covered by ISO 18562-2).
- References to EU Regulation (EU) 2017/745 are provided (Annex ZA) for use in demonstrating conformity.
EN ISO 18562-2:2024 is essential for anyone responsible for ensuring breathing gas pathway safety, reducing respirable particulates, and documenting compliance in healthcare respiratory equipment.
Технические детали
- Технический комитет
- VAZ - Healthcare
- SKU
- SIST EN ISO 18562-2:2024
Похожие стандарты
Стандарты, упомянутые в описании
ISO 18562-2:2024
ДействующийBiocompatibility evaluation of breathing gas pathways in healthcare applications — Part 2: Tests for emission…
Overview ISO 18562-2:2024 specifies how to evaluate particulate matter emissions from breathing gas pathways in healthcare applications. It is part of the ISO 18562 series on biocompatibility evaluat…
ISO 18562-1:2024
ДействующийBiocompatibility evaluation of breathing gas pathways in healthcare applications — Part 1: Evaluation and tes…
Overview ISO 18562-1:2024 provides a comprehensive framework for the biocompatibility evaluation of breathing gas pathways in medical devices used in healthcare settings. This standard is fundamental…